Most new hepatitis C infections in New York are among younger adults. Hepatitis C screening tests are available for everyone 18 years or older, those at risk who are under 18 and every pregnant person during each pregnancy. Visit: health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/testing/
December 18, 2025 at 2:06 PM
Most new hepatitis C infections in New York are among younger adults. Hepatitis C screening tests are available for everyone 18 years or older, those at risk who are under 18 and every pregnant person during each pregnancy. Visit: health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/testing/
AbbVie Seeks Extended Approval for Gracaprevir/Velpatasvir in Acute Hepatitis C Treatment in Japan#Japan#Tokyo#Hepatitis_C#Gracaprevir#Velpatasvir
AbbVie Seeks Extended Approval for Gracaprevir/Velpatasvir in Acute Hepatitis C Treatment in Japan
AbbVie has submitted a request for approval of gracaprevir/velpatasvir for treating acute hepatitis C in Japan, potentially expanding treatment options in the country.
third-news.com
July 16, 2026 at 5:22 AM
AbbVie Seeks Extended Approval for Gracaprevir/Velpatasvir in Acute Hepatitis C Treatment in Japan#Japan#Tokyo#Hepatitis_C#Gracaprevir#Velpatasvir
AbbVie Gains EU Approval for MAVIRET® to Treat Acute Hepatitis C Vulnerable Patients#None#AbbVie#Hepatitis_C#MAVIRET®
AbbVie Gains EU Approval for MAVIRET® to Treat Acute Hepatitis C Vulnerable Patients
AbbVie's MAVIRET® is now authorized in the EU for acute hepatitis C treatment, enhancing timely intervention for millions at risk.
third-news.com
June 23, 2026 at 9:20 AM
AbbVie Gains EU Approval for MAVIRET® to Treat Acute Hepatitis C Vulnerable Patients#None#AbbVie#Hepatitis_C#MAVIRET®
AbbVie's MAVIRET® Secures Positive Recommendation for Acute Hepatitis C Treatment in Europe#USA#AbbVie#North_Chicago#Hepatitis_C#MAVIRET
AbbVie's MAVIRET® Secures Positive Recommendation for Acute Hepatitis C Treatment in Europe
AbbVie has received a positive opinion from the CHMP for MAVIRET® to treat acute hepatitis C infections, benefiting both adults and children. This treatment aims to enhance early intervention and HCV elimination.
third-news.com
May 22, 2026 at 12:13 PM
AbbVie's MAVIRET® Secures Positive Recommendation for Acute Hepatitis C Treatment in Europe#USA#AbbVie#North_Chicago#Hepatitis_C#MAVIRET
Hepatitis B and C Therapeutics Market Expected to Reach $17.02 Billion by 2024, Driven by Advances in Treatment and Screening Policies#USA#Austin#Hepatitis_B#Hepatitis_C#Antivirals
Hepatitis B and C Therapeutics Market Expected to Reach $17.02 Billion by 2024, Driven by Advances in Treatment and Screening Policies
The Hepatitis B and C therapeutics market is projected to hit $17.02 billion by 2024, fueled by innovations in treatment and national screening strategies that enhance global healthcare.
third-news.com
November 19, 2025 at 4:23 PM
Hepatitis B and C Therapeutics Market Expected to Reach $17.02 Billion by 2024, Driven by Advances in Treatment and Screening Policies#USA#Austin#Hepatitis_B#Hepatitis_C#Antivirals
AbbVie's Mavyret Gains FDA Approval for Acute Hepatitis C Treatment#United_States#AbbVie#MAVYRET#Hepatitis_C#North_Chicago,_Illinois
AbbVie's Mavyret Gains FDA Approval for Acute Hepatitis C Treatment
AbbVie has received FDA approval for Mavyret, the first and only treatment for acute Hepatitis C patients, allowing immediate intervention upon diagnosis.
third-news.com
July 15, 2025 at 4:28 AM
AbbVie's Mavyret Gains FDA Approval for Acute Hepatitis C Treatment#United_States#AbbVie#MAVYRET#Hepatitis_C#North_Chicago,_Illinois
AbbVie's MAVYRET® Gains FDA Approval for Acute Hepatitis C Treatment#United_States#AbbVie#North_Chicago#MAVYRET#Hepatitis_C
AbbVie's MAVYRET® Gains FDA Approval for Acute Hepatitis C Treatment
AbbVie’s MAVYRET® becomes the first eight-week treatment for acute hepatitis C, paving the way for better patient outcomes and disease management.
third-news.com
June 11, 2025 at 4:41 PM
AbbVie's MAVYRET® Gains FDA Approval for Acute Hepatitis C Treatment#United_States#AbbVie#North_Chicago#MAVYRET#Hepatitis_C